Key result
Intravenous agents for advanced heart failure are currently restricted to short-term infusion for acute decompensation or long-term application as a bridge in heart transplantation candidates.
Why the study?
The role of intravenous agents for advanced heart failure patients has changed profoundly due to the standard use of oral neurohumoral antagonists.
Intravenous therapy in advanced heart failure is currently restricted to short-term stabilization in acute decompensation or as a bridge to transplantation.
Answers are grounded in this paper and cite their sources.
Limits IV agents to short-term support in decompensated NYHA IV HF; leaves open optimal selection and duration.
Because of the standard use of oral neurohumoral antagonists, the role of intravenous agents for advanced heart failure patients has changed profoundly. Their current use as medical therapy is restricted to two indications: first, as short-term infusion (hours to days) in advanced heart failure patients who decompensate into a symptomatic New York Heart Association class IV condition and who are admitted for rapid hemodynamic support with intravenous vasodilators or inotropes; in these patients after hemodynamic and clinical stabilization, optimization of conventional heart failure therapy has to be reconsidered; second, as long-term application in heart transplantation candidates who are in a similar desperate condition although already receiving maximal oral heart failure therapy.
No takes yet. Share an insight, caveat, or question.
Stanek et al. (2000) conducted a review in Advanced heart failure. Intravenous therapy (vasodilators or inotropes) was evaluated. Intravenous agents for advanced heart failure are currently restricted to short-term infusion for acute decompensation or long-term application as a bridge in heart transplantation candidates.
Synapse has enriched 10 related papers. Consider them for comparative context: